 |
|
  |
 |
The rise of the dragon in bioinformatics A highly advanced system is being introduced in the field of genomics and drug discovery. For the past three years our scientists have been developing generic in-silico platforms, tagged "Dragon", aimed at supporting the cutting edge R&D. With great accuracy and rich functional abilities, Dragon is fast establishing itself as a prominent name in bioinformatics. Most of the research and developmental work related to Dragon systems has been published in scientific journals, thus conforming to the highest scientific standards in the field. Over the past 18 months, effort of our team has concentrated on the development of endocrinology informatics. This field can be related to various medical problems ranging from cancer to hormonal disorders, while numerous medical applications are also foreseen. The Dragon systems are comprised of a number of efficient software solutions which handle different issues, such as the analysis of anonymous DNA, gene regulatory networks, and related text-mining. The most well-known of these are recognition of promoter regions of genes and recognition of estrogen response elements. Dragon Promoter Finder and Dragon Gene Start Finder have sparked the interest of scientists around the world. Besides being licensed to Biobase, Germany, Dragon Gene Start Finder has been tested on the human genome in a recent joint study with Sugano Lab, Human Genome Center, Japan, and has emerged as the most accurate promoter prediction system among seven evaluated systems. Dragon ERE Finder has also achieved a distinction. Its usefulness has been confirmed through a clinical study of estrogen receptor status in breast cancer performed in the National Cancer Center, Singapore. This study has since been published in one of the reputed journals, Human Molecular Genetics. As a further proof of its effectiveness, this system has predicted three new genes which directly bind estrogen receptor, as confirmed in an experimental study in the Genome Institute of Singapore. This year, the team is hoping to release the first system that can accurately detect estrogen target genes through a quick, affordable in-silico method, with a level of accuracy similar to that featured in microarray experiments. Additionally, the team also aims to pioneer the release of a database of transcriptional regulatory patterns of estrogen target genes. If everything goes according to the plan, this discovery could cut by half the cost and time required for drug development experiments in this field.
For enquiries / explore collaboration, please contact:
 |
|
|
 |
 |
||||
|
|||||
top
home |
